Palvella doses first patients in Phase 2 trial of QTORIN™ rapamycin for rare angiokeratomas

Palvella Therapeutics has begun dosing patients in its Phase 2 LOTU trial to test QTORIN™ 3.9% rapamycin gel for treating clinically significant angiokeratomas, a rare and debilitating skin condition with no FDA-approved treatments. The trial will enroll up to 15 patients in the U.S. and evaluate safety and efficacy, with topline results expected in late 2027. This trial builds on recent advances classifying angiokeratomas as lymphatic malformations, supporting the use of mTOR inhibitors like QTORIN™ rapamycin. The treatment aims to offer a non-invasive alternative to current painful and scarring procedures.